Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine’s SEC documents are packed with clinical data, trial endpoints and cash-burn tables that easily stretch beyond 200 pages. Finding where a Phase 2 read-out moved the needle or which executive exercised stock options can feel like searching for a gene variant in a genome.
Stock Titan solves that problem. Our AI parses every new 10-Q quarterly earnings report, 10-K annual report and 8-K material event the moment IRON files with EDGAR. Plain-language summaries surface R&D spend, milestone payments and risk factors, while real-time alerts flag Disc Medicine insider trading Form 4 transactions so you never miss a director’s buy or sell. Need to answer “How do I read Disc Medicine’s proxy statement executive compensation section?”—we highlight the exact tables in seconds.
Use the platform to:
- Track pipeline progress through 8-K trial disclosures explained simply
- Compare quarter-over-quarter cash runway with AI-annotated 10-Q trends
- Monitor Disc Medicine Form 4 insider transactions real-time for confidence signals
- Dive into “Disc Medicine annual report 10-K simplified” to spot hepcidin-pathway strategy updates
Whether you type “understanding Disc Medicine SEC documents with AI” into ChatGPT or ask Google for “Disc Medicine earnings report filing analysis,” this page delivers. Every filing, every footnote—decoded, searchable and always current.
SEC Form 4 filing (07/25/2025) discloses that Disc Medicine (IRON) director Kevin Bitterman executed two open-market sales through affiliated Atlas Venture funds.
- 07/23/2025: 29,837 common shares sold at a weighted-average price of $60.97.
- 07/24/2025: 13,033 common shares sold at a weighted-average price of $61.17.
Following the transactions, Bitterman’s indirect ownership via Atlas funds decreased from roughly 676,839 to 633,969 shares. He also continues to hold an additional 420,549 shares in Opportunity II and 51,000 shares in Atlas XII, keeping his total indirect stake above 1.1 million shares. Bitterman remains a board member and reports no derivative activity.
FAQ
What is the current stock price of Disc Medicine (IRON)?
What is the market cap of Disc Medicine (IRON)?
